Products - Oesophageal cancer | Topic | NICE

Showing 10 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 January 2027
Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [TSID12301]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC